The minimum required level of donor chimerism in hereditary hemophagocytic lymphohistiocytosis

Blood

Volumn 127, Issue 25, 2016, Pages 3281-3290

  Hartz, Bernd ^a   Marsh, Rebecca ^b   Rao, Kanchan ^c   Henter, Jan Inge ^d   Jordan, Michael ^b   Filipovich, Lisa ^b   Bader, Peter ^e   Beier, Rita ^f,g   Burkhardt, Birgit ^h   Meisel, Roland ⁱ   Schulz, Ansgar ^j   Winkler, Beate ^a,k   Albert, Michael H ^l   Greil, Johann ^m   Karasu, Gülsün ⁿ   Woessmann, Wilhelm ^o   Corbacioglu, Selim ^p   Gruhn, Bernd ^q   Holter, Wolfgang ^r,s   Kühl, Jörn Sven ^t   Lang, Peter ^u   Seidel, Markus G ^r,v   Veys, Paul ^c   Löfstedt, Alexandra ^d   Ammann, Sandra ^w   Ehl, Stephan ^w   Janka, Gritta ^a   Müller, Ingo ^a   Lehmberg, Kai ^a   more..

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^c GREAT ORMOND STREET HOSPITAL   (United Kingdom)

^d KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^e UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^f HANNOVER MEDICAL SCHOOL   (Germany)

^g UNIVERSITY HOSPITAL ESSEN   (Germany)

^h UNIVERSITY HOSPITAL MÜNSTER   (Germany)

ⁱ UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^j UNIVERSITY HOSPITAL ULM   (Germany)

^k UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^l LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^m UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

ⁿ BAHCESEHIR UNIVERSITY   (Turkey)

^o UNIVERSITY HOSPITAL GIESSEN   (Germany)

^p UNIVERSITY HOSPITAL REGENSBURG   (Germany)

^q JENA UNIVERSITY HOSPITAL   (Germany)

^r MEDICAL UNIVERSITY OF VIENNA   (Austria)

^s UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^t CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^u UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^v MEDICAL UNIVERSITY OF GRAZ   (Austria)

^w UNIVERSITY OF FREIBURG   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CD3 ANTIGEN; CD56 ANTIGEN; CORTICOSTEROID; DEXAMETHASONE; ETOPOSIDE; INFLIXIMAB; METHYLPREDNISOLONE; RITUXIMAB; TACROLIMUS;

ADOLESCENT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CENTRAL NERVOUS SYSTEM; CENTRAL NERVOUS SYSTEM DISEASE; CHILD; CHIMERA; CYTOMEGALOVIRUS; DISEASE EXACERBATION; DONOR; DONOR CHIMERISM; EPSTEIN BARR VIRUS; FEMALE; GENETIC DISORDER; GRAFT VERSUS HOST REACTION; HEMOPHAGOCYTIC SYNDROME; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; MYELOABLATIVE CONDITIONING; NEWBORN; OUTCOME ASSESSMENT; POSTTRANSPLANT LYMPHOPROLIFERATIVE DISEASE; PRIORITY JOURNAL; RECURRENCE RISK; RECURRENT DISEASE; REDUCED INTENSITY CONDITIONING; REMISSION; RETROSPECTIVE STUDY; RISK ASSESSMENT; VIREMIA; ADULT; ADVERSE EFFECTS; ALLOTRANSPLANTATION; CLINICAL TRIAL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY; IMMUNOLOGY; LYMPHOHISTIOCYTOSIS, HEMOPHAGOCYTIC; MULTICENTER STUDY; PRESCHOOL CHILD; PROCEDURES; TRANSPLANTATION CONDITIONING; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; CHIMERISM; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INFANT; INFANT, NEWBORN; LYMPHOHISTIOCYTOSIS, HEMOPHAGOCYTIC; MALE; RECURRENCE; RETROSPECTIVE STUDIES; TISSUE DONORS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION IMMUNOLOGY; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84977554525     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2015-12-684498     Document Type: Article

References (27)

1. Henter JI, Horne A, Aricó M, et al. HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2007;48(2):124-131.
2. Janka GE, Lehmberg K. Hemophagocytic syndromes - an update. Blood Rev. 2014;28(4):135-142.
3. Baker KS, Filipovich AH, Gross TG, et al. Unrelated donor hematopoietic cell transplantation for hemophagocytic lymphohistiocytosis. Bone Marrow Transplant. 2008;42(3):175-180.
4. Horne A, Janka G, Maarten Egeler R, et al; Histiocyte Society. Haematopoietic stem cell transplantation in haemophagocytic lymphohistiocytosis. Br J Haematol. 2005;129(5):622-630.
5. Ouachée-Chardin M, Elie C, de Saint Basile G, et al. Hematopoietic stem cell transplantation in hemophagocytic lymphohistiocytosis: a single-center report of 48 patients. Pediatrics. 2006; 117(4):e743-e750.
6. Cooper N, Rao K, Goulden N, Webb D, Amrolia P, Veys P. The use of reduced-intensity stem cell transplantation in haemophagocytic lymphohistiocytosis and Langerhans cell histiocytosis. Bone Marrow Transplant. 2008;42(Suppl 2):S47-S50.
7. Lehmberg K, McClain KL, Janka GE, Allen CE. Determination of an appropriate cut-off value for ferritin in the diagnosis of hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2014;61(11):2101-2103.
8. Marsh RA, Vaughn G, Kim MO, et al. Reduced-intensity conditioning significantly improves survival of patients with hemophagocytic lymphohistiocytosis undergoing allogeneic hematopoietic cell transplantation. Blood. 2010;116(26):5824-5831.
9. Marsh RA, Jordan MB, Filipovich AH. Reduced-intensity conditioning haematopoietic cell transplantation for haemophagocytic lymphohistiocytosis: an important step forward. Br J Haematol. 2011;154(5):556-563.
10. Marsh RA, Rao MB, Gefen A, et al. Experience with alemtuzumab, fludarabine, and melphalan reduced-intensity conditioning hematopoietic cell transplantation in patients with nonmalignant diseases reveals good outcomes and that the risk of mixed chimerism depends on underlying disease, stem cell source, and alemtuzumab regimen. Biol Blood Marrow Transplant. 2015;21(8):1460-1470.
11. Terrell CE, Jordan MB. Mixed hematopoietic or T-cell chimerism above a minimal threshold restores perforin-dependent immune regulation in perforin-deficient mice. Blood. 2013;122(15):2618-2621.
12. Cooper N, Rao K, Gilmour K, et al. Stem cell transplantation with reduced-intensity conditioning for hemophagocytic lymphohistiocytosis. Blood. 2006;107(3):1233-1236.
13. Marsh RA, Bleesing JJ, Filipovich AH. Using flow cytometry to screen patients for X-linked lymphoproliferative disease due to SAP deficiency and XIAP deficiency. J Immunol Methods. 2010;362(1-2):1-9.
14. Bryceson YT, Pende D, Maul-Pavicic A, et al. A prospective evaluation of degranulation assays in the rapid diagnosis of familial hemophagocytic syndromes. Blood. 2012;119(12):2754-2763.
15. Schneider EM, Lorenz I, Müller-Rosenberger M, Steinbach G, Kron M, Janka-Schaub GE. Hemophagocytic lymphohistiocytosis is associated with deficiencies of cellular cytolysis but normal expression of transcripts relevant to killer-cell-induced apoptosis. Blood. 2002;100(8):2891-2898.
16. Wheeler RD, Cale CM, Cetica V, Aricò M, Gilmour KC. A novel assay for investigation of suspected familial haemophagocytic lymphohistiocytosis. Br J Haematol. 2010;150(6):727-730.
17. Marsh RA, Kim MO, Liu C, et al. An intermediate alemtuzumab schedule reduces the incidence of mixed chimerism following reduced-intensity conditioning hematopoietic cell transplantation for hemophagocytic lymphohistiocytosis. Biol Blood Marrow Transplant. 2013;19(11):1625-1631.
18. Marsh RA, Rao K, Satwani P, et al. Allogeneic hematopoietic cell transplantation for XIAP deficiency: an international survey reveals poor outcomes. Blood. 2013;121(6):877-883.
19. Straathof KC, Rao K, Eyrich M, et al. Haemopoietic stem-cell transplantation with antibody-based minimal-intensity conditioning: a phase 1/2 study. Lancet. 2009;374(9693):912-920.
20. Zhang K, Jordan MB, Marsh RA, et al. Hypomorphic mutations in PRF1, MUNC13-4, and STXBP2 are associated with adult-onset familial HLH. Blood. 2011;118(22):5794-5798.
21. Pagel J, Beutel K, Lehmberg K, et al. Distinct mutations in STXBP2 are associated with variable clinical presentations in patients with familial hemophagocytic lymphohistiocytosis type 5 (FHL5). Blood. 2012;119(25):6016-6024.
22. Risdall RJ, McKenna RW, Nesbit ME, et al. Virus-associated hemophagocytic syndrome: a benign histiocytic proliferation distinct from malignant histiocytosis. Cancer. 1979;44(3):993-1002.
23. DiCarlo J, Agarwal-Hashmi R, Shah A, et al. Cytokine and chemokine patterns across 100 days after hematopoietic stem cell transplantation in children. Biol Blood Marrow Transplant. 2014; 20(3):361-369.
24. Koyama M, Sawada A, Yasui M, Inoue M, Kawa K. Encouraging results of low-dose etoposide in the treatment of early-onset hemophagocytic syndrome following allogeneic hematopoietic stem cell transplantation. Int J Hematol. 2007;86(5):466-467.
25. Abdelkefi A, Ben Jamil W, Torjman L, et al. Hemophagocytic syndrome after hematopoietic stem cell transplantation: a prospective observational study. Int J Hematol. 2009;89(3):368-373.
26. Takagi S, Masuoka K, Uchida N, et al. High incidence of haemophagocytic syndrome following umbilical cord blood transplantation for adults. Br J Haematol. 2009;147(4):543-553.
27. Kobayashi R, Tanaka J, Hashino S, et al. Etoposide-containing conditioning regimen reduces the occurrence of hemophagocytic lymphohistiocytosis after SCT. Bone Marrow Transplant. 2014;49(2):254-257.